ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,842.63
1.12%
Dow Jones
43,006.59
1.14%
US Dollar vs MXN
20.4134
-0.63%
Brent Oil
69.265
-2.49%
Bitcoin
90,727.91
4.01%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. ATAI Life Sciences NV (ATAI)

  7. ATAI Life Sciences NV (ATAI) Noticias

ATAI

ATAI Life Sciences NV (ATAI)

ATAI Life Sciences NV
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ATAI
FechaHoraFuenteTítuloSímboloCompañía
05/03/202515:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATAIATAI Life Sciences NV
05/03/202506:00GlobeNewswire Inc.atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant DepressionNASDAQ:ATAIATAI Life Sciences NV
24/02/202520:59Edgar (US Regulatory)Form SCHEDULE 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:ATAIATAI Life Sciences NV
24/02/202515:10GlobeNewswire Inc.atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care ConferenceNASDAQ:ATAIATAI Life Sciences NV
20/02/202506:00GlobeNewswire Inc.atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common SharesNASDAQ:ATAIATAI Life Sciences NV
13/02/202515:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATAIATAI Life Sciences NV
13/02/202515:35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATAIATAI Life Sciences NV
12/02/202521:47GlobeNewswire Inc.atai Life Sciences Announces Pricing of Public Offering of Common SharesNASDAQ:ATAIATAI Life Sciences NV
12/02/202515:01GlobeNewswire Inc.atai Life Sciences Announces Proposed Public Offering of Common SharesNASDAQ:ATAIATAI Life Sciences NV
28/01/202506:00GlobeNewswire Inc.atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use DisorderNASDAQ:ATAIATAI Life Sciences NV
10/01/202515:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATAIATAI Life Sciences NV
10/01/202506:00GlobeNewswire Inc.atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental HealthNASDAQ:ATAIATAI Life Sciences NV
13/11/202407:00GlobeNewswire Inc.atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ATAIATAI Life Sciences NV
11/11/202406:30GlobeNewswire Inc.Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial OfficerNASDAQ:ATAIATAI Life Sciences NV
15/10/202407:00GlobeNewswire Inc.atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual SummitNASDAQ:ATAIATAI Life Sciences NV
04/09/202406:00GlobeNewswire Inc.atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ATAIATAI Life Sciences NV
13/08/202406:10GlobeNewswire Inc.atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ATAIATAI Life Sciences NV
13/08/202406:00GlobeNewswire Inc.atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)NASDAQ:ATAIATAI Life Sciences NV
07/08/202406:00GlobeNewswire Inc.atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:ATAIATAI Life Sciences NV
26/06/202406:00GlobeNewswire Inc.atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives ConferenceNASDAQ:ATAIATAI Life Sciences NV
20/06/202406:00GlobeNewswire Inc.atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2aNASDAQ:ATAIATAI Life Sciences NV
31/05/202406:00GlobeNewswire Inc.atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare ConferenceNASDAQ:ATAIATAI Life Sciences NV
23/05/202406:00GlobeNewswire Inc.atai Life Sciences Strengthens Board with Appointment of Two New Independent DirectorsNASDAQ:ATAIATAI Life Sciences NV
15/05/202406:53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATAIATAI Life Sciences NV
15/05/202405:59GlobeNewswire Inc.atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ATAIATAI Life Sciences NV
24/04/202406:00GlobeNewswire Inc.atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant DepressionNASDAQ:ATAIATAI Life Sciences NV
17/04/202406:00GlobeNewswire Inc.atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of PsychopharmacologyNASDAQ:ATAIATAI Life Sciences NV
28/03/202406:00GlobeNewswire Inc.atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical HighlightsNASDAQ:ATAIATAI Life Sciences NV
27/03/202406:00GlobeNewswire Inc.atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant DepressionNASDAQ:ATAIATAI Life Sciences NV
04/03/202407:00GlobeNewswire Inc.atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01NASDAQ:ATAIATAI Life Sciences NV
 Showing the most relevant articles for your search:NASDAQ:ATAI

Su Consulta Reciente

USOTC
ADDYY
Adidas (QX)
COIN
BTCUSD
Bitcoin
USOTC
RHHBY
Roche (QX)
NYSE
MCD
McDonalds
CCOM
US500
US 500
NASDAQ
MSFT
Microsoft
PM
XAUUSD
Gold vs US Dollar
NYSE
VZ
Verizon Communications
USOTC
DTEGY
Deutsche Telekom (QX)
CCOM
US30
US 30
NASDAQ
QQQ
Invesco QQQ Trust Series 1
FX
USDMXN
US Dollar vs MXN
COIN
ETHUSD
Ethereum
AMEX
XLF
Financial Select Sector
NASDAQ
AMZN
Amazon.com
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios